Resolution of bowel obstruction in a patient with hereditary angioedema treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study

被引：3

作者：

Cicardi, Marco ^{[1
]}

Zingale, Lorenza C. ^{[1
]}

Zanichelli, Andrea ^{[1
]}

机构：

[1] Univ Milan, Osepdale San Giuseppe AFaR, Ist Med Interna, Milan, Italy

来源：

MOLECULAR IMMUNOLOGY | 2007年 / 44卷 / 1-3期

关键词：

D O I：

10.1016/j.molimm.2006.07.035

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：160 / 160

页数：1

共 13 条

[1] A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
Cicardi, Marco
Zingale, Lorenza C.
Zanichelli, Andrea
MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 161
[2] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema
Caballero, T
López-Serrano, C
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 476 - 477
[3] Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema
Anne, R
Deveras, E
Bracho, F
BLOOD, 2004, 104 (11) : 113B - 114B
[4] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Lehmann, Andreas
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1187 - 1199
[5] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema - Reply
Beck, TR
Baird, LG
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 477 - 477
[6] DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema
Cicardi, M
Gonzalez-Quevedo, T
Caballero, T
Bork, K
Williams, A
MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 197 - 198
[7] Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary Angioedema - Successful treatment with DX-88, a human plasma kallikrein inhibitor
Zingale, Lorenza C.
Zanichelli, Andrea
Deliliers, Daniela Lambertenghi
Cicardi, Marco
ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL-JOURNAL OF THE WORLD ALLERGY ORGANIZATION, 2007, 19 (04): : 159 - 163
[8] DX-88 a recombinant inhibitor of human plasma kallikrein. Evalation of efficacy and safety in patients with hereditary angioedema
Williams, T
Cicardi, M
Bork, K
Gonzalez-Quevedo, T
Caballero, T
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) : 908 - 908
[9] Results of a repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88), a recombinant plasma kallikrein inhibitor, in patients with hereditary angioedema.
Lumry, W.
Li, H.
Schneider, L.
Leflein, J.
Craig, T.
Morrison, J.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A29 - A29
[10] Results of a 2-stage, phase 3 pivotal trial, EDEMA3®:: A study of subcutaneous DX-88 (ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema (HAE)
Levy, R.
McNeil, D.
Li, H.
Hsu, F. I.
Horn, P.
Roberts, J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S103 - S103

← 1 2 →